Cancer biotech BIND Therapeutics sets terms for $71 million IPO

By Renaissance Capital,

Shutterstock photo

BIND Therapeutics, a clinical-stage biotech developing a platform of targeted and programmable therapeutics, announced terms for its IPO on Thursday. The Cambridge, MA-based company plans to raise $71 million by offering 4.7 million shares at a price range of $14 to $16. At the midpoint of the proposed range, BIND Therapeutics would command a market value of $237 million.

BIND Therapeutics, which was founded in 2006 and booked $5 million in sales for the 12 months ended June 30, 2013, plans to list on the NASDAQ under the symbol BIND. BIND Therapeutics initially filed confidentially on June 28, 2013. Credit Suisse and Cowen & Company are the joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: BIND

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by